Not Yet RecruitingNot Applicable

Personalized Mobile Reminders for Medication Adherence and Intraocular Pressure Control in Primary Open-Angle Glaucoma

84 participantsStarted 2026-04-01

Plain-language summary

This study evaluates whether a personalized mobile reminder program improves treatment adherence and clinical outcomes in adults with primary open-angle glaucoma (POAG) using topical antiglaucoma eye drops. Poor adherence to long-term eye-drop therapy is common in glaucoma care and may contribute to inadequate intraocular pressure (IOP) control and disease progression. Participants are randomized to either (1) a digital adherence intervention or (2) standard outpatient follow-up. The intervention consists of daily interactive SMS/WhatsApp medication reminders plus weekly brief educational messages for 3 months. The primary outcome is change in medication adherence measured by the Morisky Medication Adherence Scale-8 (MMAS-8) at month 3. Secondary outcomes include change in IOP, eye-drop instillation technique, and treatment satisfaction. Exploratory analyses assess the relationship between adherence level and OCT-based retinal nerve fiber layer (RNFL) progression metrics. The goal is to determine whether a low-cost, scalable mobile strategy can improve short-term glaucoma management in routine practice.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Adults aged 18 to 75 years. Diagnosis of primary open-angle glaucoma (POAG) in at least one eye. Currently treated with at least one topical antiglaucoma medication. Able to read and understand study procedures and provide written informed consent. Has regular access to a mobile phone capable of receiving SMS or WhatsApp messages. Willing to comply with follow-up visits and study procedures for 3 month Exclusion Criteria: Secondary glaucoma (e.g., neovascular, uveitic, steroid-induced) or angle-closure glaucoma. Ocular surgery or laser procedure within the previous 3 months, or planned ocular surgery during study follow-up. Advanced ocular comorbidity likely to affect IOP assessment or adherence evaluation (e.g., severe corneal disease, active ocular infection/inflammation). Cognitive impairment, severe psychiatric disease, or communication barriers that prevent reliable participation. Inability to use or access mobile messaging tools required for the intervention. Participation in another interventional clinical study that may interfere with outcomes

What they're measuring

Change in Medication Adherence

Timeframe: Baseline and Month 3

Trial details

NCT IDNCT07480577

SponsorSakarya Yenikent State Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-01